Mechanistic and Structural Insights on Difluoromethyl-1,3,4-oxadiazole Inhibitors of HDAC6.

DFMO hydrolysis LC-MS NMR X-ray crystallography difluoroacetylhydrazide (DFAcH) difluoromethyl-1,3,4-oxadiazole (DFMO) enzyme kinetics histone deacetylase 6 (HDAC6) non hydroxamic inhibitors

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
28 May 2024
Historique:
received: 24 04 2024
revised: 20 05 2024
accepted: 22 05 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 19 6 2024
Statut: epublish

Résumé

Histone deacetylase 6 (HDAC6) is increasingly recognized for its potential in targeted disease therapy. This study delves into the mechanistic and structural nuances of HDAC6 inhibition by difluoromethyl-1,3,4-oxadiazole (DFMO) derivatives, a class of non-hydroxamic inhibitors with remarkable selectivity and potency. Employing a combination of nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography-mass spectrometry (LC-MS) kinetic experiments, comprehensive enzymatic characterizations, and X-ray crystallography, we dissect the intricate details of the DFMO-HDAC6 interaction dynamics. More specifically, we find that the chemical structure of a DMFO and the binding mode of its difluoroacetylhydrazide derivative are crucial in determining the predominant hydrolysis mechanism. Our findings provide additional insights into two different mechanisms of DFMO hydrolysis, thus contributing to a better understanding of the HDAC6 inhibition by oxadiazoles in disease modulation and therapeutic intervention.

Identifiants

pubmed: 38892072
pii: ijms25115885
doi: 10.3390/ijms25115885
pii:
doi:

Substances chimiques

Oxadiazoles 0
Histone Deacetylase 6 EC 3.5.1.98
Histone Deacetylase Inhibitors 0
HDAC6 protein, human EC 3.5.1.98
1,3,4-oxadiazole 20O2F20OUR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Edoardo Cellupica (E)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Aureliano Gaiassi (A)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Ilaria Rocchio (I)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Grazia Rovelli (G)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Roberta Pomarico (R)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Giovanni Sandrone (G)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Gianluca Caprini (G)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Paola Cordella (P)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Cyprian Cukier (C)

Department of Biochemistry, Selvita S.A., 30-394 Kraków, Poland.

Gianluca Fossati (G)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Mattia Marchini (M)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Aleksandra Bebel (A)

Department of Biochemistry, Selvita S.A., 30-394 Kraków, Poland.

Cristina Airoldi (C)

Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.

Alessandro Palmioli (A)

Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.

Andrea Stevenazzi (A)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Christian Steinkühler (C)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Barbara Vergani (B)

Research and Development, Italfarmaco Group, 20092 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH